Table 1.
BEVS-based health-related products of interest.
| Table | Commercial Name | Manufacturer | Target (Organism/Disease) | Composition | Clinical Stage | Year of Approval */Phase III Trial | Reference |
|---|---|---|---|---|---|---|---|
| Human vaccines | Cervarix® | GlaxoSmithKline | human papillomaviruses 16 and 18 | VLPs of L1 proteins from HPV 16 and 18 | Approved | 2007 * | [155] |
| Flublok® Quadrivalent | Sanofi Pasteur | influenza virus | HA from 4 different strains of influenza A and B | Approved | 2016 * | [156] | |
| Nuvaxoid™/Covovax™ | Novavax | SARS-CoV-2 | S protein | Approved | 2022 * | [157] | |
| N/A | West China Hospital of Sichuan University | SARS-CoV-2 | S RBD (residues 319-545) | Phase III | 2021 | [158] | |
| N/A | Sanofi Pasteur/GlaxoSmithKline | SARS-CoV-2 | S (pre-fusion state) without its transmembrane domain | Phase III | 2021 | [159] | |
| NanoFlu™ | Novavax | Influenza virus | HA, NA and M1 proteins | Phase III | 2019 | [160] | |
| N/A | Novavax | Influenza viruses and SARS-CoV-2 | HA and Spike (recombinant) nanoparticles | Phase I/II | N/A | [161] | |
| Veterinary products | Porcilis Pesti® | MSD Animal Health | Pestivirus C (CSFV) (Classical swine fever) | E2 protein | Approved (withdrawn from UE market) | 2009 * | [162] |
| Circumvent® PCV-M G2 | MSD Animal Health | Porcine circovirus 2, Mycoplasma hyopneumoniae | ORF2, non replicative antigen of Mycoplasma hyopneumoniae | Approved | 2013 * | [163] | |
| Bayovac® CSF-E2 | Bayer AG/Pfizer Animal Health | Pestivirus C (CSFV) (Classical swine fever) | E2 protein | Approved | 2000 * | [164] | |
| Ingelvac CircoFLEX® | Boehringer Ingelheim | Porcine circovirus 2 | ORF2 | Approved | 2008 * | [165] | |
| Circumvent® PCV A | Merck Animal Health | Porcine circovirus 2 | ORF2 | Approved | 2005 * | [166] | |
| Porcilis PCV® A | MSD Animal Health | Porcine circovirus 2 | ORF2 | Approved | 2005 * | [167] | |
| INTERDOG™ | TORAY Industries, Inc. | Treatment of atopic dermatitis in dogs | Canine gamma interferon | Approved in Japan | 2005 * | [168] | |
| Virbagen® Omega | Virbac | Treatment of infections with feline leukemia virus (FeLV) and/or feline immunodeficiency virus (FIV) | Feline omega interferon | Approved | 2001 * | [169] | |
| Gene Therapy | Glybera® | uniQure | Lipoprotein lipase deficiency | Adeno-associated vector with LPL gene | Approved (withdrawn from market in 2017 due to high cost) | 2012 * | [170] |
| Others | Diamyd® | Diamyd | Type I diabetes | GAD65 | Phase III | 2021 | [171] |
| Provenge® | Dendreon Pharmaceuticals | Prostate cancer | PAP-GM-CSF fusion protein | Approved | 2010 * | [172] |
A Same product but licensed under different names depending on geographic region.